Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | July 2026 | YoY |
|---|---|---|
| Revenue | 368.01K | 58.52% |
| Gross profit | 313.85K | 44.72% |
| Net profit | -1.83M | 15.36% |
| EBITDA | -1.68M | 12.29% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.82M |
Number of shares | 277.49M |
52-week high/low | €0.0554 - €0.0245 |
| Dividends | No |
Beta | 1.22 |
P/E ratio | -1.41 |
PEG ratio | -0.01 |
P/B ratio | 1.53 |
P/S ratio | 6.55 |
Company profile
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
| Name | BIOVICA INTERNATIONAL |
| CEO | Theis Kipling |
| Headquarters | Uppsala,
up Sweden |
| Website | |
| IPO | 03/29/2017 |
| Employees | 24 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | BIOVIC-B.ST |
Frankfurt | 9II.F |
Stockholm | BIOVIC B.ST |
München | 9II.MU |
